These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37699634)

  • 81. Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002).
    Wang J; Guan Y; Gu W; Yan S; Zhou J; Huang D; Tong T; Li C; Cai S; Zhang Z; Zhu J
    Radiat Oncol; 2019 Nov; 14(1):215. PubMed ID: 31783766
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial.
    Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Ariyoshi K; Oyamada S; Iwase S
    BMJ Open; 2018 Jul; 8(7):e021442. PubMed ID: 30030317
    [TBL] [Abstract][Full Text] [Related]  

  • 83. RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial.
    Burbach JP; Verkooijen HM; Intven M; Kleijnen JP; Bosman ME; Raaymakers BW; van Grevenstein WM; Koopman M; Seravalli E; van Asselen B; Reerink O
    Trials; 2015 Feb; 16():58. PubMed ID: 25888548
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.
    Velenik V; Ocvirk J; Music M; Bracko M; Anderluh F; Oblak I; Edhemovic I; Brecelj E; Kropivnik M; Omejc M
    Radiat Oncol; 2011 Aug; 6():105. PubMed ID: 21880132
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05).
    Takahashi S; Ohno I; Ikeda M; Kobayashi T; Akimoto T; Kojima M; Konishi M; Uesaka K
    BMJ Open; 2017 Oct; 7(10):e018445. PubMed ID: 29061632
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
    Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG
    BMJ Open; 2020 Jan; 10(1):e033667. PubMed ID: 31988233
    [TBL] [Abstract][Full Text] [Related]  

  • 87. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 88. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
    Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
    [TBL] [Abstract][Full Text] [Related]  

  • 90. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effects of pre-operative enteral immunonutrition for esophageal cancer patients treated with neoadjuvant chemoradiotherapy: protocol for a multicenter randomized controlled trial (point trial, pre-operative immunonutrition therapy).
    Cao Y; Han D; Yang S; Shi Y; Zhao S; Jin Q; Li J; Li C; Zhang Y; Shen W; He J; Wang M; Ji G; Li Z; He Y; Chen Q; Wei W; Chen C; Gong X; Wang J; Tan L; Wang H; Li H
    BMC Cancer; 2022 Jun; 22(1):650. PubMed ID: 35698100
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
    Rahma OE; Yothers G; Hong TS; Russell MM; You YN; Parker W; Jacobs SA; Colangelo LH; Lucas PC; Gollub MJ; Hall WA; Kachnic LA; Vijayvergia N; O'Rourke MA; Faller BA; Valicenti RK; Schefter TE; George S; Kainthla R; Stella PJ; Sigurdson E; Wolmark N; George TJ
    JAMA Oncol; 2021 Aug; 7(8):1225-1230. PubMed ID: 34196693
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
    Lutsyk M; Awawda M; Gourevich K; Ben Yosef R
    Am J Clin Oncol; 2021 Sep; 44(9):482-486. PubMed ID: 34269693
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.
    Lu C; Zhu Y; Kong W; Yang J; Zhu L; Wang L; Tang M; Chen J; Li Q; He J; Li A; Qiu X; Gu Q; Chen D; Meng F; Liu B; Qiu Y; Du J
    Front Oncol; 2022; 12():879661. PubMed ID: 36059628
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer.
    Yang Z; Ma J; Han J; Li A; Liu G; Sun Y; Zheng J; Zhang J; Chen G; Xu R; Sun L; Meng C; Gao J; Bai Z; Deng W; Zhang C; Su J; Yao H; Zhang Z
    Med; 2024 Oct; 5(10):1293-1306.e4. PubMed ID: 39047732
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial.
    Spaas M; Sundahl N; Hulstaert E; Kruse V; Rottey S; De Maeseneer D; Surmont V; Meireson A; Brochez L; Reynders D; Goetghebeur E; Van den Begin R; Van Gestel D; Renard V; Dirix P; Mestdagh P; Ost P
    BMC Cancer; 2021 May; 21(1):514. PubMed ID: 33962592
    [TBL] [Abstract][Full Text] [Related]  

  • 98. First in human intraarterial delivery of tislelizumab for the treatment of pMMR locally advanced rectal cancer: A single-arm, open label, phase II clinical trial.
    Yang W; Qian C; Luo J; Chen C; Feng Y; Dai N; Li X; Xiao H; Yang Y; Li M; Li C; Wang D
    Transl Oncol; 2024 Dec; 50():102154. PubMed ID: 39405605
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).
    O'Cathail SM; Davis S; Holmes J; Brown R; Fisher K; Seymour L; Adams R; Good J; Sebag-Montefiore D; Maughan T; Hawkins MA
    Radiat Oncol; 2020 Jun; 15(1):151. PubMed ID: 32532291
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial.
    Chopra S; Goda JS; Mittal P; Mulani J; Pant S; Pai V; Kannan S; Deodhar K; Krishnamurthy MN; Menon S; Charnalia M; Shah S; Rangarajan V; Gota V; Naidu L; Sawant S; Thakkar P; Popat P; Ghosh J; Rath S; Gulia S; Engineer R; Mahantshetty U; Gupta S
    BMJ Open; 2022 Apr; 12(4):e055765. PubMed ID: 35387819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.